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Summary
The recommendations of international scientific societies
for the treatment of hypertension in the geriatric population
are different. Lack of outcome trials, non-standardised ter-
minology as well as differing levels of evidence contribute
to the inconsistencies in the guidelines. This review article
compares six international guidelines (ESH-ESC 2007/
2009, SHG 2009, DHL 2008, CHEP 2010, NICE 2011
and JNC7 2003) as well as the consensus document of
the ACCF/AHA 2011 in terms of their recommendations
of drug classes, target blood pressure values and the use
of combination therapy. Generally, antihypertensive ther-
apy appears to be clinically beneficial in geriatric patients.
Target blood pressure values of <140–150/90 mm Hg and
<140/90 mm Hg can be used as a general guideline for oc-
togenarians (80–89 yrs) and septuagenarians (70–79 yrs)
respectively. While angiotensin-II converting enzyme in-
hibitors and diuretics appear to be advantageous in treating
combined systolic-diastolic hypertension, calcium-channel
blockers and diuretics are to be recommended in the man-
agement of isolated systolic hypertension. Combination
therapy often increases the efficacy of the treatment as well
as patient medication adherence. Furthermore, by making
the most of drug combination synergy, lower doses may be
used resulting in fewer side-effects.
Key words: hypertension; international guidelines; blood
pressure; treatment; elderly
Introduction
It is estimated that, by 2050, approximately a fifth of the
global geriatric population will be 80 years or above [1].
Because the majority of these patients are diagnosed and
treated in earlier life years, the cardiovascular sequalae are
delayed until a greater age. Despite the increase of life ex-
pectancy within the last few decades and the significant in-
crease in the size and proportion of geriatric patients, blood
pressure (BP) control rates in old and very old patients re-
mains low [2]. Up to 75% of this population does not meet
target BPs. Inconsistencies within international guidelines
appear to be generally underestimated, but may contrib-
ute to low BP control-rates in this particular populace. We
have identified the following points as sources of conflict-
ing opinion:
– Lack of information: Only a few scientific societies
provide therapeutic recommendations for elderly
patients. The rapid release of new data within the last
few years is not yet reflected by all national societies,
making such information inaccessible to health
practioners and patients alike.
– Lack of evidence: target BPs are not clearly defined
and are mainly based on expert opinion.
– Varying level of evidence: There is disparity amongst
different guidelines with regards to the level of
evidence upon which recommendations are based.
– Non-standardised terminology: Almost all published
guidelines, use different or novel terms for defining
age ranges within the geriatric populace.
– Different approaches for the use of combined therapy:
Therapy failure is often due to the apprehension of
side effects and an increased pill burden which results
in poor adherence in the elderly.
The aim of this review is to investigate six international
guidelines with respect to their recommendations on target
BPs, drug classes and combination therapy for old and very
old patients and to highlight the current information in the
Consensus Document of the American College of Cardi-
ology Foundation / American Heart Association (ACCF /
AHA 2011) [3].
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Selection of guidelines
Worldwide, there is in excess of 100 guidelines for the
treatment of hypertension (HT). The inhabitants of Europe
(739 million), the U.S. (310 million) and Canada (31 milli-
on) represent about one-seventh of the world’s population
[4] and have a high proportion of elderly patients. To rep-
resent these areas, we have chosen three continental-scope
recommendations (European Society of Hypertension /
ESH-ESC 2007 [5] and Reappraisal 2009 [6] for Europe,
and the Canadian Hypertension Education Program /
CHEP 2010 [7] as well as the Joint National Committee
on Prevention, Detection, Evaluation, and Treatment of
High Blood Pressure JNC7 2003 [8] for North America).
Due to existing differences within European health systems
(National Health Service*, model of social insurance**,
model of private insurance***) we decided to compare
the guidelines of the UK* (National Institute for Health
and Clinical Excellence / NICE 2011 [9], Germany**
(Deutsche Hochdruckliga [German Society of Hyperten-
sion] / DHL 2008 [10]) and Switzerland*** (Swiss Society
of Hypertension/SHG 2007/2008 [11]).
Treatment recommendations and
target blood pressures
The concept of guidelines for the diagnosis and treatment
of HT is a simple and pragmatic idea: BP thresholds are
defined, where initiating pharmacological treatment and
implementing lifestyle changes, have been proven to be
clinical beneficial [3]. While target BPs can be easily speci-
fied in younger patients owing to the large number of relev-
ant outcome studies, consistent and specific long-term out-
come data are decidedly lacking for patients older than 79
years. An overview of selected outcome trials for patients
in the elderly and very elderly is shown in table 1.
A crucial source of inconsistency in the limited available
studies is the non-standardised terminology. For instance,
whilst the terms “elderly” (“old”) and “very elderly” (“very
old”) are widely used in the literature, their defined age
ranges differ as per table 2. The ACCF / AHA 2011 [3]
saw, for the first time, an attempt the stratify old age into
“young old” (65–74 years), “older old” (75–84 years) and
“old old” (85 years and above) [3]. This allowed for the ap-
plication of definitive age-specific target BPs.
Further confounding the research is the entrenched concept
of “long-term” studies as spanning at least four (4) years.
In the case of the elderly, such spans are difficult to study,
as the remaining life expectancy of old patients (8 years in
2002) may be less than this time period [12].
The evolution of guideline recommendations for the treat-
ment of HT in the elderly saw a significant turning point
with the publication of the Hypertension in the Very
Elderly Trial (HYVET) [13]. HYVET was carried out
primarily as a trial concerning the “old old” population and
demonstrated a 30% reduction of stroke and a 23% reduc-
tion of cardiovascular morbidity and fatal events.
Pre-HYVET: Considering the limited number of patients
>79 years who were included in trials, no conclusive state-
ment about specific target BPs could be given. Up until
2007 it was even questionable whether treatment of hyper-
tension per se was beneficial in the very elderly [14]. Al-
though it had been shown that a target BP <140/90 mm Hg
significantly reduces cardiovascular risk in middle-aged
patients, only one single study was conducted in elderly
patients (65–85 years) applying this target and showed no
clinical benefit [15]. In addition, no studies had ever been
conducted on patients >79 years with stage I HT (140–159
mm Hg) [16].
Due to this lack of evidence, a “general” target BP recom-
mendation for patients >80 years was lacking in the avail-
able guidelines or included within the recommendations for
the population <65 years. For instance, a target BP of <140/
90 mm Hg was maintained in the ESH-ESC 2007.
As a result, in a survey conducted in 2002 one quarter of
doctors were of the opinion that the treatment of HT ap-
portioned more risks than benefits to patients >85 years
[17]. The same study also showed that approximately 65%
of general practitioners were aware of a target systolic BP
(SBP) of <140 mm Hg, yet 58% opted to initiate antihyper-
tensive therapy only at a SBP >160 mm Hg [17].
Post-HYVET: Increasing evidence could be found of the
impact of HYVET on guidelines. The ESH-ESC 2009 [6]
recommends the HYVET target BP (SBP <150 mm Hg) in
patients >80 years [8], citing potentially intolerable side-ef-
fects when aiming for a target BP of <140 mm Hg. Simil-
arly, NICE 2011 [9] and DHL 2008 [10] recommend target
BPs of <150/80 mm Hg in octogenarians. The SHG 2009
[11] favours a general target BP of <150/90 mm Hg, irre-
spective of whether a patient is “old” or “very old”. Differ-
ent from this, CHEP 2010 [7] does not allude to a specif-
ic target BP. The ACCF / AHA 2011 [3] recommendation
concerns a systolic target BP range of ≤140–150 mm Hg
for patients >79 years depending one or more criteria or
contingencies (table 3).
Is “lower” better?
Data from the Honululu Heart Program suggest that ex-
cessive reduction of BP not only affects quality of life but
can also increase cardiovascular risk [18]. A recent cohort
study partly confirmed this in the elderly, demonstrating
that both sustained, as well as regression of, DPB <70 mm
Hg were independently associated with heart failure [34].
Thus, a significant increase in mortality has been shown in
INVEST [19] when SBP or DBP drops below 115 mm Hg
or 65 mm Hg respectively. Observational data indicate that
the lowest target BP for attributable risk in septuagenarians
is <135/75 mm Hg and <140/70 mm Hg for octogenarians
[3].
However, the question remains whether certain co-morbid-
ities (such as chronic renal disease, heart failure etc.) will
benefit from more stringent target BPs. Neither the invest-
igated guidelines nor the ACCF / AHA 2011 [3] take a
clear stance on this. Despite existing expert opinion de-
manding that BP be lowered to <130/80 mm Hg in high-
risk patients, there is currently little clinical evidence to
support this. This question was raised within the Cardio-Sis
study [20], which showed lower event rates in the “young
old” with a systolic target BP of <130 mm Hg instead of
<140 mm Hg. In contrast, the primary results of ACCORD
[21] yielded no difference in event rates when a systolic
target BP of <120 mm Hg or <140 mm Hg was applied.
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Also, the assessment of cardiovascular risk by Framingham
(and therefore the decision on how far the blood pressure
should be lowered) is limited by its non-applicability to pa-
tients >70 years.
It is known that orthostatic hypotension (supine-to-stand-
ing BP drop of >20 or >10 mm Hg for SBP and DBP re-
spectively) is known to occur more frequently (5–30%) in
the elderly (patients >65 years) [33]. With regards to this
condition the ESH-ESC 2009 [6] mentions an increased
risk in the elderly on anti-HT therapy and advises routine
standing BP measurements, but makes no treatment recom-
mendations. Both DHL 2008 [10] and CHEP 2009 [7] re-
commend routine standing BP measurements and recom-
mend that elderly patients should be tested for postural hy-
potension. Furthermore, DHL 2008 [10] emphasises lower
initial drug doses in elderly patients. The JNC7 2003 [8]
advises periodic standing BP measurements and mentions
orthostatic hypotension as a potential complication of poly-
pharmacy. Neither NICE 2011 [9] nor SHG 2009 [11] men-
tion standing BP measuring or orthostatic hypotension.
Additionally, it should be adressed, that physicians have in-
creasingly the responsibility to be the “manager” of death.
This also refers to the establishment and expansion of an-
tihypertensive therapy in situations of advanced malignant
diseases. An overview of the recommendations of the
guidelines is shown in table 3.
Drug recommendations
Although, unsurprisingly, significant BP reductions could
be shown for all classes of drugs (in comparison to
placebo), the efficacy differences appear to be marginal.
Where, for instance, benefit has been shown for calcium
channel blockers (CCB) and sartans (angiotensin-II recept-
or blocker, ARB) over beta blockers (BB) in LIFE [22] and
SCOPE [23], the DHL 2008 [10], ESH-ESC 2007 [5] (and
ESH-ESC 2009 [6]) and CHEP 2009 [7] do not express a
preference for any specific drug classes on the basis of age.
In contrast, the SHG 2009 [11] mentions the superior effic-
acy of diuretics (D) compared to BB. Therefore BB should
not be used in the elderly [24], seeing as the results are not
convincing for older patients [25]. In addition, a meta-ana-
lysis of 10 studies with BB and D in patients over 60 years
showed that about 2/3 of the patients were well-controlled
on D alone [26].
The ACCF/AHA 2011 [3] stresses, therefore, that initial
therapy should, if possible be a D (hydrochlorothiazide
[HCTZ], chlorthalidone, bendrofluazide) [3] and if another
Table 1: Summary of important outcome trials for patients in the elderly and very elderly.
Trial Age of
included
patients
(years)
N Inclusion Criteria
SBP / DBP
(mm Hg)
Goal
SBP / DBP
(mm Hg)
Active
Treatment
Control BP Δ
SBP / DBP
(mm Hg)
Clinical
benefit
Results
SHEP ≥60 4736 160–219 / <90 <160, ↓20 D
BB
placebo –12 / –4 + ↓ CV events (32%)
↓ stroke (36%)
↔ CV mortality
STOP
(subgroup)
70–84 1627 ≥180 / ≥90
OR DBP >105
<160 / <95 BB
D
placebo –19 SBP + ↓ CV events (40%)
↓ stroke (46%)
↓ CV mortality (43%)
HYVET ≥80 3845 >160 / <110 <150 / <80 D
ACEI
placebo –15 / –6.1 + ↓ CV events (34%)
↓ stroke (30%)
↓ CV mortality (23%)
SYST.EUR ≥60 4695 160–219 / <95 SBD <150 CCB
ACEI
D
placebo –10 / –5 + ↓ CV events (26%)
↓ stroke (42%)
↓ CV mortality (27%)
SCOPE 70–89 4937 160–179 / 90-99 <160 / 90 ARB placebo –4.7 / –2,6 + ↓ CV events (11%)
↓ stroke (24%)
↔ CV mortality
LIFE-ISH 55–80 1326 160–200 / <90 ≤140 / 90 ARB BB –16,7 / –9.0 + ↓ CV events (27%)
↓ stroke (43%)
↓ CV mortality (47%)
SHEP Systolic Hypertension in the Elderly Program, STOP Swedish Trial in Old Patients with hypertension, HYVET HYpertension in the Very Elderly Trial, SYST.EUR
SYSTolic hypertension in EURope trial, SCOPE The Study on Cognition and Prognosis in the Elderly, LIFE-ISH. The Losartan Intervention For Endpoint reduction in
hypertension – Isolated Systolic Hypertension Subgroup, SBP systolic blood pressure, DBP diastolic blood pressure, D diuretic, BB beta-blocker, ACEI angiotensin
converting enzyme inhibitor, ARB angiotensin-II receptor blocker, ↓ reduction in outcome, ↔ no difference in outcome
Table 2: Applied age definitions within investigated guidelines.
Age term ESH-ESC
2007 [5]
(years)
ESH-ESC
2009 [6]
(years)
JNC7
2003 [8]
(years)
CHEP
2010 [7]
(years)
DHL
2008 [10]
(years)
SHG
2009 [11]
(years)
NICE
2011 [9]
(years)
ACCF/AHA
2011 [3]
(years)
Adults – <65 <65 <60 <60 – <55 <65
Old
(elderly)
– 65–79 65–x 60–x 60–79 – 65–79
Very old
(very elderly)
≥80 ≥80 – ≥80 ≥80 – ≥80
65–74 (young old)
75–84 (older old)
≥85 (old old)
ESH-ESC 2007 Guidelines for the Management of Arterial Hypertension, ESH-ESC 2009 Reappraisal of European guidelines on hypertension management, JNC9 The
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, CHEP The 2010 Canadian Hypertension
Education Program recommendations for the management of hypertension, DHL 2008 Leitlinien zur Behandlung der arteriellen Hypertonie, SHG 2009 Schweizerische
Hypertonie-Gesellschaft, NICE 2011 Clinical management of primary hypertension in adults, ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly
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class were prescribed as first-line, the second drug should
always be a D.
In a change from its previous version, NICE 2011 [9] re-
commended in 2011 initial treatment with a CCB or, if a
CCB is unsuitable owing to e.g. oedema or intolerance, a
“thiazide-like” D (indapamide / chlorthalidone) for all pa-
tients >55 yrs. This treatment recommendation remains un-
affected even in the presence of ISH. If BP remains uncon-
trolled, either an ACE inhibitor (ACEI) or ARB is to be
added as a second drug.
The JNC7 2003 [8] pursued a more rigid strategy, recom-
mending that the treatment of older patients follow the
same principles as for younger patients, regardless of the
presence of a systolic-diastolic HT or ISH. Similar to the
SHG 2009 [11], a BB should preferably be used for young-
er patients.
Is there an “ideal combination”?
HYVET saw the first data emerge regarding the use com-
bined of D and ACEI therapy in old and very old patients.
An inhibitor of the renin-angiotensin-aldosterone system
(RAAS) and a D – in particular HCTZ – have a synergistic
pharmacological effect (inhibition of an-
giotensin-2-associated salt retention, vasoconstriction, and
volume reduction). However, the use of HCTZ is limited
in diabetics as thiazides reduce glucose tolerance. A clear
superiority has been shown in ACCOMPLISH [27] for the
combination of ACEI + CCB compared to ACEI + D (re-
lative risk reduction of 21% for cardiovascular events).
This effect was independent of age (either older or younger
than 80 years). It is noteworthy that the superiority of the
ACEI + CCB combination could not be explained by dif-
ferences in BP. This result implies a possible class effect of
antihypertensive drugs in certain populations, beyond the
measurable therapeutic efficacy of these substances.
For the treatment of ISH, the ESH-ESC 2007 [5] recom-
mends the use of CCB and D. While DHL 2008 [10] re-
commendations cite the results of underlying studies, the
importance of initiating treatment with a CCB is stressed.
Although CCBs have been proven to be successful in the
Table 3: Hypertension treatment recommendations for the elderly and very elderly according to investigated guidelines.
Age ESH-ESC
2007[5]
ESH-ESC
2009[6]
JNC7
2003[8]
CHEP
2010[7]
DHL
2008[10]
SHG
2009[11]
NICE
2011[9]
Old (elderly) ≤140/90Recommended
target BP
(mmHg)
Very old
(very elderly)
– SBP ≤150
if ≥160
initially
≤140/90 ≤150/80 – ≤150/90
Old
(elderly)
All (D, CCB, ARB, ACEI, BB) All,
no BB
All All
(esp. D)
no BB
D, CCBRecommended
substances
Very old
(very elderly)
– D, CCB
Old
(elderly)
SHEP, STOP, SYST.EUR,
SCOPE, HYVET
– LIVE
SCOPE
– –Mentioned trials
Very old
(very elderly)
– HYVET – HYVET – –
Old
(elderly)
YesIs a treatment
generally recommended?
Very old
(very elderly)
Benefit remains
unclear;
cont. treatment
if well tolerated
Depends on
health condition;
individualise
treatment
– yes
Old
(elderly)
D, CCB – D, ARB,
CCB
(≤140/90)
D, CCB, ARB –
(SBP ≤150)
D/CCB +
ACEI/ARB
(≤140/90)
Recommendations
for ISH
(target BP in mm Hg)
Very old
(very elderly)
–
ACCF/AHA 2011[3]
Recommended target BP:
<79 years: SBP <140 mm Hg
≥80 years: SBP <140–150 mm Hg
(lower limit if SBD <150 mm Hg can easily be attained
with one or two drugs;
higher limit if therapy regimen is complex, intolerable
side effects, DBP drops <65 mm Hg)
LVH CAD HF CVD CKD
ACEI, ARB BB, CCB possible
reduced EF: ACEI
ACS: BB, ACEI
D, BB, ACEI,
aldosterone –AAG;
if ACEI is not
tolerated: ARB
D + ACEI ARB, ACEI
if non-diabetic
nephropathy: ACEI
if proteinuria: ARB
PVD DM MS Uncomplicated HT
ACEI or ARB + BB ACEI or ARB – Thiazide-D, CCB, ACEI, ARB, BB
ESH-ESC 2007 Guidelines for the Management of Arterial Hypertension, ESH-ESC 2009 Reappraisal of European guidelines on hypertension management, JNC9 The
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, CHEP The 2010 Canadian Hypertension
Education Program recommendations for the management of hypertension, DHL 2008 Leitlinien zur Behandlung der arteriellen Hypertonie, SHG 2009 Schweizerische
Hypertonie-Gesellschaft, NICE 2011 Clinical management of primary hypertension in adults, ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly,
target BP target blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, D diuretic, CCB calcium channel blocker, ARB angiotensin-II receptor blocker,
ACEI angiotensin-II converting enzyme inhibitor, BB beta-blocker, LVH left ventricular hypertrophy, CAD coronary artery disease, HF heart failure, CVD cerebrovascular
disease, CKD chronic kidney disease, EF ejection fraction, ACS acute coronary syndrome, PVD peripheral vascular disease, DM diabetes mellitus, MS metabolic
syndrome, HT hypertension
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treatment of ISH, the potential for dose escalation is limited
due to the relatively common side effect peripheral oedema
[28]. New studies show that the combination of HCTZ with
an ACEI or ARB may reduce the incidence of oedema [28].
CHEP 2010 [7] expands upon the recommendation of ini-
tial treatment with D and CCB by specifying ARB as an al-
ternative. The ACCF / AHA 2011 [3] indirectly address the
treatment of ISH with their treatment recommendations for
“complicated” hypertension (table 3). The SHG 2009 [11]
and JNC7 2003 [8] guidelines contain no recommendation
for the treatment of ISH (table 3).
Combination therapies in elderly
patients
The right choice of drugs and application modes have an
influence on efficacy and tolerability [29]. As a result the
establishment of therapy is often associated with a subject-
ive decrease in quality of life, owing to an increased pill
burden and adverse drug reactions. Adding insult to injury,
elevated BP in the geriatric population is often asympto-
matic, even in the presence of end-organ damage or serious
comorbidities and the perceived low “benefit-to-risk ratio”
is unacceptable to patients.
Polypharmacy is a particularly unfortunate reason for poor
adherence [30] and high discontinuation rate, as it not only
increase the responder rates by up to 70% [31] but may
also reduce side-effects by neutralising counter-regulatory
mechanisms [32]. The increased pill burden of polyphar-
macy may be circumvented by single-pill combinations,
which also have the added benefit of component syner-
gism, requiring lower individual drug dosages and lower-
ing the occurrence of side-effects.
Severe, mono-therapy resistant HT is common in the old
and very old and in most cases this necessitates the use of
combination therapy. The rationale for this therapeutic ap-
proach is reinforced by the fact that additional end-organ
damage or comorbidities are common in this population.
The use of combination therapies in older patients is expli-
citly recommended in ESH-ESC 2007 [5] and in DHL 2008
[10]. Initial combination therapy is especially attractive in
patients with high cardiovascular risk [14] and should be
initiated for BP-to-target BP differences ≥20/10 mm Hg
[10]. This opinion is also shared by ACCF / AHA 2011
[3] and CHEP 2010 [7]. Although the 2009 ESC-ESH Re-
appraisal, as well as NICE 2011 [9] advocate gradual dose
titration (up to maximum dose), both guidelines discuss the
advantage of single-pill combinations. Differing from this,
the ACCF / AHA 2011 [3] allows the use of an additional
drug, even if the maximum dose for the initial drug has not
been reached yet.
Are combined therapies always beneficial?
Despite the therapeutic benefit of combination therapy and
increased compliance of single pill combinations in old and
very old patients, their use is not without risks. Therefore,
the use of combination products as first-line treatment (re-
gardless of the degree of hypertension) is not generally re-
commended. It must not be forgotten that BP can drop sub-
stantially in elderly patients with a primary initiation of
a combination therapy. Since up to 18% of octogenarians
show an impairment of cortical function or dementia, a lack
of adherence to a single-pill combination must be taken
more seriously, as an omission of combined (and often
long-acting) substances often lead to loss of BP control.
Concluding remarks
The investigated global guidelines differ in their treatment
and target BP recommendations. These differences are due
to the relatively immature field of study, which has seen de-
velopment only in the last five years, but also by the differ-
ent levels of underlying evidence. As a result, national and
international societies deal with this topic with varying ap-
proaches. This may lead to uncertainty amongst both gen-
eral practitioners and specialists [3]. Whilst the DHL 2008
[10] provides extended information, the comments of SHG
2009 [11] and JNC7 2003 [8] are marginal. The ACCF /
AHA 2011 [3], an “expert consensus”, represents the first
document that provides detailed information on data devel-
opment within the past eight years. However, several un-
resolved issues still remain and need to be clarified in the
future:
– Continuation of the development of the new definitions
“young old”, “older old” and “old old”. Even though
the ACCF / AHA 2011 mentions this new terminology
it still refers to “patients ≤79 years” and “patients >79
years” (i.e., with 80 years being the cut-off between
the two groups). This terminology must be clarified.
– High-level evidence such as RCTs regarding the
benefits for different target BPs (<150 vs. <140 mm
Hg) are lacking and should be conducted.
– It is recommended that geriatric subgroups
demonstrating atypical clinical responses to
pharmacotherapy (i.e. patients in whom drugs have
higher/lower efficacy) be identified.
– It is still unclear to what degree BP goals need to be
adapted in old and very old patients with additional
risk factors and/or end-organ damage.
Because of the incomplete evidence, currently no recom-
mendation can be made for the treatment of HT in the eld-
erly and very elderly with absolute confidence. However,
the following principles may be taken as general
guidelines:
1. Older patients benefit equally to younger patients from
antihypertensive treatment.
2. Target blood pressures:
– For octogenarians (>80 years) – a target BP of
<140–150/90 mm Hgshould be applied to regardless
of additional risk factors.
• The ideal target BP is <140/90 mm Hg and
should be attempted if BP control (SBP <150
mmHg) can be accomplished by the use of by
one or two drugs.
• Alternatively, if a) more than three drugs are ne-
cessary, b) unacceptable side effects occur or c)
treatment hypotension develops (DBP drops be-
low 65 mmHg), a target BP of <150/90 mm Hg
is acceptable.
Review article Swiss Med Wkly. 2012;142:w13574
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– For septuagenarians (>70 years) and patients as young
as 65 years – a target BP of <140/90 mm Hg is
appropriate.
3. Drug choices
– There is some evidence for the greater efficacy of
ACEI + D for combined systolic/diastolic HT.
– D should, whenever possible, be part of the therapy.
– CCB and D should be used in patients with ISH.
– Combination therapy, especially single-pill
combinations, should be considered as it is effective in
reducing side effects and in increasing efficacy and
patient adherence.
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